DOCSLIB.ORG

EMCDDA Monographs Are Comprehensive Scientific Publications Containing Thematic Papers Prepared in the Context of the Centre’S Activities

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EMCDDA Monographs Are Comprehensive Scientific Publications Containing Thematic Papers Prepared in the Context of the Centre’S Activities ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA's partners, any EU Member State or any agency or institution of the European Union or European Communities. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu). Europe Direct is a service to help you find answers to your questions about the European Union Freephone number: 00 800 6 7 8 9 10 11 This publication should be referenced as: EMCDDA (2008), A cannabis reader: global issues and local experiences, Monograph series 8, Volume 1, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. References to chapters in this monograph should include, where relevant, references to the authors of each chapter, together with a reference to the wider publication. For example: Corrigan, D. (2008), ‘The pharmacology of cannabis: issues for understanding its use’, in: A cannabis reader: global issues and local experiences, Monograph series 8, Volume 1, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. The publication is available on the Internet at: http://www.emcdda.europa.eu/publications/monographs/cannabis Cataloguing data can be found at the end of this publication. Luxembourg: Office for Official Publications of the European Communities, 2008 ISBN 978-92-9168-311-6 © European Monitoring Centre for Drugs and Drug Addiction, 2008 Reproduction is authorised provided the source is acknowledged. Printed in Belgium Rua da Cruz de Santa Apolónia 23–25, P-1149-045 Lisbon Tel. (351) 21 811 30 00 • Fax (351) 21 813 17 11 [email protected] • http://www.emcdda.europa.eu Contents Introduction ix Foreword xiii Wolfgang Götz Overview of Volume 1 xvii Sharon Rödner Sznitman and Börje Olsson Part I: Cannabis in the past Chapter 1: Cannabis as medicine in Europe in the 19th century 3 Manfred Fankhauser Chapter 2: The re-emergence of the therapeutic use of cannabis products: recent developments and future prospects 17 John Witton Chapter 3: The pharmacology of cannabis: issues for understanding its use 27 Desmond Corrigan Chapter 4: Soma, the Wootton Report and cannabis law reform in Britain during the 1960s and 1970s 39 Stephen Abrams Chapter 5: Cannabis’s role in drawing attention to ‘the drugs problem’ in Sweden 51 Börje Olsson Chapter 6: Enlargement 2005: cannabis in the new EU Member States 63 Jacek Moskalewicz, Airi-Alina Allaste, Zsolt Demetrovics, Danica Klempova and Janusz Sierosławski, with Ladislav Csemy, Vito Flaker, Neoklis Georgiades, Anna Girard, Vera Grebenc, Ernestas Jasaitis, Ines Kvaternik Jenko, Richard Muscat, Marcis Trapencieris, Sharon Vella and Alenka Žagar v Contents Part II: Policies, legislation and control strategies Chapter 7: Cannabis control in Europe 97 Danilo Ballotta, Henri Bergeron and Brendan Hughes Chapter 8: In thinking about cannabis policy, what can be learned from alcohol and tobacco? 119 Robin Room Chapter 9: An open front door: the coffee shop phenomenon in the Netherlands 137 Dirk Korf Chapter 10: Cannabis policy: tightening the ties in Denmark 157 Vibeke Asmussen Chapter 11: Cannabis: a harm reduction perspective 171 Andrew Bennett Part III: Supply and production issues Chapter 12: Global cannabis cultivation and trafficking 187 Ted Leggett and Thomas Pietschmann Chapter 13: Monitoring cannabis availability in Europe: issues, trends and challenges 215 Chloé Carpentier, Meredith Meacham and Paul Griffiths Chapter 14: Understanding cannabis potency and monitoring cannabis products in Europe 239 Leslie King Chapter 15: Multinational export–import ventures: Moroccan hashish into Europe through Spain 261 Juan Francisco Gamella and Maria Luisa Jiménez Rodrigo Chapter 16: An analysis of the significance of supply and market factors for variations in European cannabis use 291 Leif Lenke Appendix: Grey literature list 300 Index 311 vi Introduction Smoked, eaten, imbibed — or just talked about — it seems the world has a strong appetite for cannabis. An estimated one in five European adults have tried it. Thirteen million Europeans have consumed it in the past month. Globally, nearly 50 000 tonnes of cannabis herb or resin is produced for consumption each year. Little wonder, then, that cannabis has become a controversial cultural and commercial phenomenon. Today, cannabis has a unique ability to divide opinion among policymakers, scientists, law enforcers, drugs professionals and consumers. This EMCDDA cannabis monograph addresses one basic question. How can I find quality information on cannabis, amid all the bias and opinion? During the editing of this monograph it soon became clear that the EMCDDA was entering an area crowded with general guides, even competing cannabis monographs. This is where the idea of a cannabis ‘reader’ emerged. Our audience — researchers, parliamentarians, drugs professionals, students, European citizens — is currently faced with an overload of professional publications. Added to this is the daily flood of information on the Internet, often crusading in nature, and sometimes misleading. This threatens to obscure the genuine progress made in cannabis research during the past two decades. The EMCDDA cannabis reader underlines the point that cannabis is not just a static, unchanging plant, but a dynamic product that is subject to gradual evolution in potency, prevalence, cultivation, legislative and public health concerns. In this monograph, leading experts provide short, sharp insights on a range of cannabis topics while offering advice on further reading for each topic. Brief editorial notes provide concise introductions to each topic, occasionally drawing attention to political sensitivities and the need for a ‘critical eye’. So this cannabis reader has a value, both as a shortcut to researchers entering the area and a synthesis for experts. You will find a wide range of views expressed in the chapters in this monograph, not all of them in agreement. The arguments, tone and conclusion of each chapter is the responsibility of the author alone, and is not necessarily endorsed or supported by the EMCDDA. This reflects the wider discourse on cannabis where different positions and perspectives often lead to different conclusions being drawn from the same evidence. We believe each chapter represents a useful contribution to the overall debate, even if their individual perspectives differ. ix Introduction Two volumes, multiple audiences: policymakers, enforcers, researchers, professionals The monograph is divided into two volumes, each comprising three sections. There are a number of reasons for the two-volume approach. While complementary, each has a slightly different audience. The first volume centres on political, legislative, commercial and social developments relating to cannabis. Its core audience thus comprises policymakers, sociologists, historians, journalists and those involved in enforcement. The second volume is very much centred on drugs professionals working in the fields of treatment, prevention and healthcare. Volume 1 • Cannabis in the past • Policies, legislation and control strategies • Supply and production issues Volume 2 • Epidemiology • Health effects of cannabis use • Prevention and treatment Changing perspectives: from global issues to local experiences What unites both volumes is an attempt to fuse general chapters with specific case studies. Within each section, you will encounter a progression from a ‘top level’ to a ‘close-up’ view of the subject. So each section begins with chapters providing a general introduction to a single cannabis issue, often of an encyclopaedic nature, together with a summary of the current state of scientific research. The monograph then ‘zooms in’ with a case study about a specific aspect of cannabis. In
Load more

Recommended publications
  • WHO Expert Committee on Drug Dependence Pre-Review ……………
    WHO Expert Committee on Drug Dependence Pre-Review …………….. Cannabis plant and cannabis resin Section 5: Epidemiology This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization 1 © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 40th Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • Cannabis Dictionary
    A MEDICAL DICTIONARY, BIBLIOGRAPHY, AND ANNOTATED RESEARCH GUIDE TO INTERNET REFERENCES JAMES N. PARKER, M.D. AND PHILIP M. PARKER, PH.D., EDITORS ii ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1 Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation.
    [Show full text]
  • Aphria 2018 Management's Discussion & Analysis
    2018 Annual Report Aphria is a worldwide leader in the production, distribution and supply of high-quality cannabis. Globally in in over over Our Mission: Led by our passion for customers and consumers, 12 countriescountries Aphria’s mission is to be the premier global cannabis company through an unrelenting commitment to our people, product quality and innovation. Our Vision: Aphria’s vision is to be the best performing cannabis com- pany globally, providing investors with access to the most accretive cannabis opportunities around the world. WE HAVE A GOOD THING GROWING. Contents Message To Shareholders 6 Management Team 8 255,000 kg combined annual production Management’s Discussion 11 One of the largest And Analysis fully-funded production capabilities in the industry in early 2019 Vic Neufeld Chief Executive Officer A key pillar to success is not just to We are increasingly bringing the Aphria quality forecast the future, but to act now story to other markets globally and leveraging new With a strong foundation in anticipation. The Executive Team, opportunities to create further shareholder value. together with amazing Board support, These results reflect the strength and discipline in place, Aphria is driving is executing on this fundamental tenet. of our leadership team. This past year, we In fiscal 2018, we embarked on numerous welcomed Jakob Ripshtein as Chief Commercial initiatives that set the standard in the Officer and Dr. Christelle Gedeon as Chief Legal sustainable long-term cannabis industry and laid the foundation Counsel. Both have exceptional experience in regulated industries and affairs and add depth for our future success.
    [Show full text]
  • EMCDDA Cannabis Reader
    ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
    [Show full text]
  • 2020 Global Report on Cannabis Policy
    2020 Global Report on Cannabis Policy October 2020 2 i Contents INTRODUCTION II U.S.A. - OREGON 101 BRAZIL 1 U.S.A. - WASHINGTON 106 CANADA 12 OUR MEMBERS 111 CHINA 20 CONTRIBUTORS 112 COLOMBIA 25 DENMARK 31 ENGLAND 37 GERMANY 45 ITALY 51 PARAGUAY 56 PERU 60 SLOVENIA 68 SOUTH AFRICA 74 SPAIN 79 THAILAND 85 URUGUAY 90 U.S.A. - CALIFORNIA 96 Global Report on Cannabis Policy theworldlawgroup.com 3 ii WLG CANNABIS GUIDE INTRODUCTION We are very pleased to announce the release of the World Law Group (“WLG”) Cannabis Guide 2020. In recent years, cannabis and products with cannabis components are one of the “hot topics” in the life sciences industry. Many countries now allow the medical use of cannabis to treat numerous conditions, including chronic pain, cancer, multiple sclerosis, and many others. Additionally, more and more countries have recently allowed the recreational use of cannabis. Finally, hemp (cannabis grown without mind-altering substances), is another burgeoning industry worldwide. Though there are international treaties in place, the production, distribution, and consumption of controlled substances (including cannabis) are still traditionally regulated by each country individually (even within the EU). Some countries still consider cannabis a dangerous illicit substance. Thus the legal landscape on cannabis and cannabis products is very fragmented and complicated, making it hard to get involved in the cannabis industry. The aim of this guide is to provide a brief overview of laws and policies regarding the use of cannabis in various jurisdictions. It briefly outlines information on the most important legal issues, from relevant legislation and general information to special requirements and risks.
    [Show full text]
  • EMCDDA Monographs Are Comprehensive Scientific Publications Containing Thematic Papers Prepared in the Context of the Centre’S Activities
    ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
    [Show full text]
  • Sources of Value in the Cannabis Industry: the Case of Canadian Public Companies
    UNIVERSITY OF LJUBLJANA SCHOOL OF ECONOMICS AND BUSINESS MASTER’S THESIS SOURCES OF VALUE IN THE CANNABIS INDUSTRY: THE CASE OF CANADIAN PUBLIC COMPANIES Ljubljana, December 2019 MARK MALIS AUTHORSHIP STATEMENT The undersigned Mark Malis, a student at the University of Ljubljana, School of Economics and Business, (hereafter: SEB LU), author of this master’s thesis with the title THE SOURCES OF VALUE IN THE CANNABIS INDUSTRY: THE CASE OF CANADIAN PUBLIC COMPANIES, prepared under supervision of Professor Aljoša Valentinčič, PhD, DECLARE 1. this master’s thesis to be based on the results of my own research; 2. the printed form of this master’s thesis to be identical to its electronic form; 3. the text of this master’s thesis to be language-edited and technically in adherence with the SEB LU’s Technical Guidelines for Written Works, which means that I cited and / or quoted works and opinions of other authors in this master’s thesis in accordance with the SEB LU’s Technical Guidelines for Written Works; 4. to be aware of the fact that plagiarism (in written or graphical form) is a criminal offence and can be prosecuted in accordance with the Criminal Code of the Republic of Slovenia; 5. to be aware of the consequences a proven plagiarism charge based on the this written final work could have for my status at the SEB LU in accordance with the relevant SEB LU Rules; 6. to have obtained all the necessary permits to use the data and works of other authors which are (in written or graphical form) referred to in this master’s thesis and to have clearly marked them; 7.
    [Show full text]
  • From Repression to Regulation: Proposals for Drug Policy Reform
    From Repression to Regulation: Proposals for Drug Policy Reform José Carlos Campero • Horacio Barrancos • Ricardo Vargas Eduardo Vergara • Daniel Brombacher • Heino Stöver • Maximilian Plenert Hans Mathieu • Catalina Niño Guarnizo / Editors José Carlos Campero • Horacio Barrancos • Ricardo Vargas Eduardo Vergara • Daniel Brombacher • Heino Stöver • Maximilian Plenert Hans Mathieu • Catalina Niño Guarnizo / Editors José Carlos Campero • Horacio Barrancos • Ricardo Vargas Eduardo Vergara • Daniel Brombacher • Heino Stöver • Maximilian Plenert Hans Mathieu • Catalina Niño Guarnizo / Editors From Repression to Regulation: Proposals for Drug Policy Reform Friedrich-Ebert-Stiftung (FES), Regional Security Cooperation Program Calle 71 nº 11-90 Bogota-Colombia Telephone (57 1) 347 30 77 Fax (57 1) 217 31 15 Email: [email protected] Commercial use of all media published by the Friedrich-Ebert-Stiftung (FES) is no permitted without consent of the FES. First edition Bogota, May 2013 ISBN 978-958-8677-19-4 Editorial coordination Juan Andrés Valderrama Design and layout Ángela Lucía Vargas Cover photograph Lucas Rodríguez Translation Silvia Varela Ian Mount Matt Chesterton Printed by Mavarac The opinions expressed in this volume are the sole responsibility of the authors and do not necessarily represent the thinking of the Friedrich Ebert Stiftung. Table of Contents FOREWORD / Hans Mathieu 19 INTRODUCTION A FEW ASPECTS OF THE CURRENT SITUATION WITH ILLEGAL DRUGS Hans Mathieu / Catalina Niño The failure of prohibitionism: A growing consensus 21
    [Show full text]
  • Cannabis in the City: Developments in Local Cannabis Regulation in Europe
    Cannabis in the City: Developments in local cannabis regulation in Europe ideas into movement AUTHORS: Tom Blickman, Katie Sandwell, and Dania Putri; Xabier Arana, Tom Decorte, Vibeke Asmussen Frank, Dirk J. Korf, Ingo Ilja Michels, Maj Nygaard-Christensen, Tim Pfeiffer-Gerschel, Heino Stöver, Bernd Werse, Frank Zobel This report draws on, and in parts reproduces, country reports written by Tom Decorte (Belgium); Vibeke Asmussen Frank & Maj Nygaard-Christensen (Denmark); Ingo Ilja Michels, Tim Pfeiffer-Gerschel, Heino Stöver & Bernd Werse (Germany); Dirk J. Korf (Netherlands); Xabier Arana (Spain); and Frank Zobel (Switzerland). These reports were produced as part of the New Approaches in Harm Reduction Policies and Practices project. EDITOR: Deborah Eade DESIGN: Guido Jelsma - www.guidojelsma.nl PUBLICATION DETAILS: Contents of the report may be quoted or reproduced for non-commercial purposes, provided that the source of information is properly cited. This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the European Commission cannot be held responsible for any use which may be made of the information contained therein. TRANSNATIONAL INSTITUTE (TNI) De Wittenstraat 25, 1052 AK Amsterdam, The Netherlands Tel: +31-20-6626608, Fax: +31-20-6757176 E-mail: [email protected] www.tni.org/drugs @DrugLawReform Drugsanddemocracy Amsterdam, March 2019 2 | Cannabis in the City: Developments in local cannabis regulation in Europe transnationalinstitute Contents Cannabis and
    [Show full text]
  • WHO Expert Committee on Drug Dependence Critical Review
    WHO Expert Committee on Drug Dependence Critical Review …………….. Cannabis and cannabis resin This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • EMCDDA Insights: Cannabis Production and Markets in Europe
    ISSN 1606-1683 ISSN TD -XD -12- 012- EN - C productionCannabis and markets Europe in About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The EMCDDA’s Insights are volumes conveying the findings of study and research on topical issues in the drugs field. EMCDDA INSIGHTS EMCDDA Price (excluding VAT) in Luxembourg: EUR 15 INSIGHTS Cannabis production and markets in Europe 12 12 How to obtain EU publications Free publications: • via EU Bookshop (http://bookshop.europa.eu); • at the European Union’s representations or delegations. You can obtain their contact details on the Internet (http://ec.europa.eu) or by sending a fax to +352 2929-42758. Priced publications: • via EU Bookshop (http://bookshop.europa.eu). Priced subscriptions (e.g. annual series of the Official Journal of the European Union and reports of cases before the Court of Justice of the European Union): • via one of the sales agents of the Publications Office of the European Union (http://publications.europa.eu/others/agents/index_en.htm). EMCDDA INSIGHTS Cannabis production and markets in Europe 12 Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright.
    [Show full text]